MetaCap

Azora Therapeutics (AZR) vs iBio (IBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

iBio is the larger company by market cap ($56.4 million vs $55.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AZR-24.51%IBIO-0.51%
+7%-13%-33%
Oct 28, 20261 yearNov 20, 2026
AZR+1.05%IBIO+4.08%
+8%+1%-5%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AZR versus IBIO key metrics
MetricAZRIBIO
Share price$3.85$0.8001
Market cap$55.00M$56.37M
1-day change-0.52%-0.11%
YTD return—-58.54%
1-year return—-23.80%
5-year return—-99.76%
EPS (TTM)$-18.09$-0.27
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$100.00K
Revenue growth (YoY)—-75.00%
Net income (latest FY)$-7.98M$-33.04M
Operating margin—-35141.00%
Net margin—-33044.00%
52-week high$8.25$3.82
52-week low$1.31$0.68
Distance from 52-week high-53.33%-79.05%
Analyst consensus—strong_buy
Avg. price target upside—+611.16%
Average volume50.12K678.91K
Shares outstanding14.29M70.46M
Employees—23
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About iBio

IBIO stock →

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

AZR vs IBIO FAQ

Which is bigger, Azora Therapeutics or iBio?

iBio (IBIO) is larger, with a market capitalization of $56.37M compared with $55.00M for Azora Therapeutics (AZR).

Are Azora Therapeutics and iBio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons